Correction to: HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging
Betül Altunay, Agnieszka Morgenroth, Mohsen Beheshti, Andreas Vogg, Nicholas C. L. Wong, Hong Hoi Ting, Hans-Jürgen Biersack, Elmar Stickeler, Felix M. Mottaghy
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMonoclonal and Polyclonal Antibodies Research · Radiopharmaceutical Chemistry and Applications · Lung Cancer Research Studies
Correction to: European Journal of Nuclear Medicine and Molecular Imaging (2021) 48:1371–1389
10.1007/s00259-020-05094-1
The authors regret that there are some errors in the original published article. The below article note should be removed.
Betül Altunay and Agnieszka Morgenroth contributed equally to this work.
On the other hand, the “Authors’ contributions” section should be corrected from:
Conceptualization, writing—original draft preparation BA, AM; writing—review and editing, all authors. All authors have read and agreed to the published version of the manuscript.
to:
Conceptualization, writing—original draft preparation BA; writing—review and editing, all authors. All authors have read and agreed to the published version of the manuscript.
The original article has been corrected.